pipette
ENEnglish

Modeling CNS inflammatory demyelination using myelin-directed CAR T cells

C. Cordano, S. Gupta, C. Guglielmetti, C. Shepherd, M. Heady, J. Duecker, A. Abdelhak, B. Ng, R. Zhu, W. Yu, S. Sagan, D. Stefanoff, J. Sin, A. Beaudry-Richard, A. Montevirgen, L. Kozanno, S. Hauser, M. Wilson, S. Zamvil, A. Green, W. A. Lim, M. Simic

Preprint

En palabras de los autores

Multiple sclerosis therapies remain confined to immunomodulatory agents that reduce inflammatory activity; none restores lost myelin, and disability can continue to accumulate independently of relapses. Development of remyelinating therapies has been hindered by models that incompletely reproduce the persistently inflamed lesions in which remyelination fails. Here we show that chimeric antigen receptor (CAR) T cells targeting myelin oligodendrocyte glycoprotein (MOG) build such lesions on demand. Human CD4+ CAR T cells transferred into immunodeficient mice infiltrated the brain, spinal cord, and optic nerve, producing perivascular demyelinating lesions, with reproducible optic nerve involvement. Within these discrete optic nerve lesions, treatment with the remyelinating compound clemastine reduced lesion size and improved optic nerve conduction, despite persistent inflammation. Thus, this MOG CAR T model reproduces key features of inflammatory demyelinating disease and enables testing of remyelinating therapies; more broadly, it introduces CAR T cells as programmable perturbative agents for building defined pathology in vivo.

Resultado principalEl resumen no menciona limitaciones.

Apareció: jueves, 19 de noviembre. bioRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.11.16.767139